Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays.
暂无分享,去创建一个
Gerard Tromp | Sorin Draghici | Karen Lu | Robert Morris | Judith Abrams | Xiaoju Wang | S. Drăghici | B. Ye | Xiaoju Wang | M. Chatterjee | M. Tainsky | G. Tromp | J. Abrams | K. Lu | S. Witkin | S. Mohapatra | A. Munkarah | Madhumita Chatterjee | Rouba Ali-Fehmi | R. Ali-Fehmi | N. Levin | Saroj Mohapatra | Alexei Ionan | Gagandeep Bawa | James Nowak | Bin Ye | Fatimah A Nahhas | Steven S Witkin | David Fishman | Adnan Munkarah | Nancy K Levin | Natalie N Shirley | Michael A Tainsky | James E. Nowak | R. Morris | David Fishman | F. Nahhas | Alexei Ionan | G. Bawa | Natalie Shirley | K. Lu | R. Morris | K. Lu | Madhumita Chatterjee
[1] Wei Chen,et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. , 1994, Cancer research.
[2] A. Abbruzzese,et al. Post-translational modifications of eukaryotic initiation factor-5A (eIF-5A) as a new target for anti-cancer therapy. , 1999, Advances in experimental medicine and biology.
[3] M. Vaarala,et al. Several genes encoding ribosomal proteins are over‐expressed in prostate‐cancer cell lines: Confirmation of L7a and L37 over‐expression in prostate‐cancer tissue samples , 1998, International journal of cancer.
[4] Douglas C Pearl,et al. Proteomic patterns in serum and identification of ovarian cancer , 2002, The Lancet.
[5] 園田 顕三. A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas , 1996 .
[6] Yao-Tseng Chen,et al. Characterization of human colon cancer antigens recognized by autologous antibodies , 1998, International journal of cancer.
[7] Y. Nakamura,et al. Multiple forms of the APC gene transcripts and their tissue-specific expression. , 1993, Human molecular genetics.
[8] A. Munkarah,et al. The effect of cyclooxygenase‐2 expression on tumor vascularity in advanced stage ovarian serous carcinoma , 2003, Cancer.
[9] R. Roden,et al. A serologically identified tumor antigen encoded by a homeobox gene promotes growth of ovarian epithelial cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[10] Gerd Ritter,et al. Immunotherapeutic Targets Cancer : Identification of Potential Diagnostic and Cancer-related Serological Recognition of Human Colon Updated , 2002 .
[11] P. Bruggen,et al. Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.
[12] X. Guan,et al. Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer. , 2001, Cancer research.
[13] D. Jäger,et al. Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. , 2001, Cancer research.
[14] J. Rousseau,et al. RCAS1 is associated with ductal breast cancer progression. , 2002, Biochemical and biophysical research communications.
[15] S. Drăghici,et al. Epitomics: serum screening for the early detection of cancer on microarrays using complex panels of tumor antigens , 2005, Expert review of molecular diagnostics.
[16] V. Alakhov,et al. Epitope-specific antibody response to HT-1080 fibrosarcoma cells by mimotope immunization. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] D. Jäger,et al. Antigens recognized by autologous antibody in patients with renal‐cell carcinoma , 1999, International journal of cancer.
[18] R. L. Baldwin,et al. Cancer incidence in a population of Jewish women at risk of ovarian cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Gordon K Smyth,et al. Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .
[20] T. Oshikiri,et al. High expression of tumor‐associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker , 2002, International journal of cancer.
[21] S. Hanash,et al. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. , 2001, Cancer research.
[22] S. Ménard,et al. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] G. Giannini,et al. New mutations and protein variants of NBS1 are identified in cancer cell lines , 2003, Genes, chromosomes & cancer.
[24] W Feiden,et al. PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme , 2001, Oncogene.
[25] Yao-Tseng Chen,et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[26] M. Kitao,et al. Clinical usefulness and false-positive results of CA 125 as a tumor marker of ovarian cancer —A study on 674 patients— , 1986, The Japanese journal of surgery.
[27] E. Diamandis. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. , 2004, Journal of the National Cancer Institute.
[28] M. Schummer,et al. Selecting Differentially Expressed Genes from Microarray Experiments , 2003, Biometrics.
[29] M. O'Rand,et al. Comparison of mouse and human NASP genes and expression in human transformed and tumor cell lines. , 2001, Gene.
[30] D. Jäger,et al. Humoral immune responses of cancer patients against “Cancer‐Testis” antigen NY‐ESO‐1: Correlation with clinical events , 1999 .
[31] M. Elwood. Proteomic patterns in serum and identification of ovarian cancer , 2002, The Lancet.
[32] W. Mastropaolo,et al. Pronounced increases in the concentration of an ovarian tumor marker, CA-125, in serum of a healthy subject during menstruation. , 1986, Clinical chemistry.
[33] N. Nomura,et al. Complete sequencing and characterization of 21,243 full-length human cDNAs , 2004, Nature Genetics.
[34] P. Schwarzenberger,et al. Early stage breast cancer. , 1997, Oncology reports.
[35] M Ferdeghini,et al. Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. , 1999, Gynecologic oncology.
[36] V. Zurawski,et al. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: Relevance for early detection of ovarian cancer , 1988, International journal of cancer.
[37] M. Pfreundschuh,et al. Human neoplasms elicit multiple specific immune responses in the autologous host. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[38] S J Rodda,et al. A priori delineation of a peptide which mimics a discontinuous antigenic determinant. , 1986, Molecular immunology.
[39] G Sybrecht,et al. Role of amplified genes in the production of autoantibodies. , 1999, Blood.
[40] A R Feinstein,et al. Academic calculations versus clinical judgments: practicing physicians' use of quantitative measures of test accuracy. , 1998, The American journal of medicine.
[41] Lori E. Dodd,et al. Partial AUC Estimation and Regression , 2003, Biometrics.
[42] F. Cohen,et al. A human gene (AHNAK) encoding an unusually large protein with a 1.2-microns polyionic rod structure. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[43] M J O'Hare,et al. Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. , 2001, Cancer immunity.
[44] Christina Gloeckner,et al. Modern Applied Statistics With S , 2003 .
[45] E. Petricoin,et al. Use of proteomic patterns in serum to identify ovarian Cancer , 2002 .
[46] M. Loda,et al. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy , 2004, International Journal of Colorectal Disease.